Analyst Ratings for Intellia Therapeutics (NTLA)
NTLA Rating Summary
NTLA Price Target Summary
- Highest: $106.00 (Brookline Capital Markets)
- Lowest: $5.00 (JPMorgan)
- Average: $26.05
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$26.05 (+105.3%)
* Over Last 12-Mos
Rating Score: 6.6 / 10
Percentile Rank: 68%
Avg. $ Target:
$26.05 (+105.3%)
* Over Last 12-Mos
Rating Score: 6.6 / 10
Percentile Rank: 68%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/6/2026 | Evercore ISI | Jonathan Miller | Upgrade | Outperform (In Line) |
24.00 (16.00) |
10.97 (12.69) |
15.68% | Details |
| 7/16/2026 | Wolfe Research | Andy Chen | Downgrade | Underperform (Peerperform) |
9.00 (N/A) |
13.30 (12.69) |
-4.59% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
